Standardized extract according to the product, with meals.
⏱ 3 min read
The artichoke, besides being a vegetable prized in Mediterranean cooking, is a medicinal plant with a long tradition of use in digestive and liver disorders; the dry extract of its leaves (not the edible heart) concentrates the relevant bioactive compounds (cynarin, chlorogenic acid, luteolin, silybin, and other polyphenols) and is the format used in the modern clinical trials that support its most serious indications.
Unlike many plant extracts with limited clinical evidence, the artichoke has several randomized controlled trials documenting modest but significant effects on lipid profile, functional dyspepsia, and some liver markers, which places it among the herbal products with reasonable support for minor digestive and metabolic indications where conventional medicine does not always have good options.
The indication with the best evidence is functional dyspepsia, that set of symptoms of postprandial fullness, abdominal bloating, belching, and heavy digestion that affect a considerable part of the population with no underlying organic pathology: several randomized trials have shown that doses of 320 to 640 milligrams daily of standardized artichoke leaf extract for 6 to 8 weeks significantly improve dyspeptic symptoms compared with placebo.
The most plausible mechanism combines stimulation of bile production and secretion (a choleretic-cholagogue effect demonstrated in mechanistic studies), modulation of gastrointestinal motility, and a mild carminative effect; this profile makes it especially useful in people with slow digestion after fatty or copious meals, where the bottleneck is often precisely the biliary response.
On lipid profile, several trials have shown modest reductions in total cholesterol (5-10 percent) and LDL (8-12 percent) with doses of 1,500 to 2,700 milligrams daily of extract over 8 to 12 weeks; the effect is comparable to that of other natural lipid-lowering agents such as garlic or psyllium, and it can be added to dietary changes or drug treatments in people with mild dyslipidemia without generating relevant interactions.
The mechanism combines inhibition of HMG-CoA reductase (the same enzyme that statins block, but far more gently) with effects on bile conjugation and intestinal cholesterol absorption; it is one of the few supplements whose lipid-lowering effect has been replicated in carefully conducted meta-analyses.
In mild chronic liver disease, especially that associated with alcohol or with non-alcoholic fatty liver, several studies have shown modest improvements in transaminases (ALT, AST, GGT) and in functional liver markers, in line with the extract's choleretic and antioxidant effect; these data are less solid than those for dyspepsia or cholesterol, but sufficient to consider it a reasonable adjunct in mild liver dysfunction under medical supervision.
The doses studied range from 320 to 2,700 milligrams daily of dry leaf extract, divided into two or three doses with meals, for at least 4-8 weeks to assess response; products standardized to chlorogenic acid or cynarin are the best clinically supported and the ones worth choosing from what the market offers.
Generally well tolerated; the most frequent adverse effects are mild digestive discomfort, flatulence, and, rarely, allergic reactions in people sensitive to plants of the Asteraceae family (composites: chamomile, ragweed, chrysanthemum); it is contraindicated in biliary tract obstruction (symptomatic cholelithiasis, cholangitis) because of the risk of precipitating biliary colic, and it is advisable to consult before using it in pregnancy and breastfeeding because of limited data.
Information, not medical advice. Scientific evidence reflects the quality of the studies.